---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-26-000554"
form_type: "8-K"
ticker: "ARTL"
cik: "0001621221"
company_name: "ARTELO BIOSCIENCES, INC."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:50:23.594081+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Artelo expands ART27.13 development for muscle preservation with GLP-1 therapies

## Summary
- ART27.13 to be evaluated as companion therapy to prevent muscle loss in patients on GLP-1 receptor agonists for weight reduction.
- Preclinical study initiated; provisional patent filed covering use of CB2 agonists with GLP-1 drugs.
- Independent research validated ART27.13 as a superagonist among 17 clinically studied CB2 agonists.
- Muscle protective effect observed in CAReS trial (cancer cachexia) and preclinical reversal of myotoxicity.
- J.P. Morgan projects global incretin market to reach $200B by 2030; ~25M Americans on GLP-1 by 2030.

## SEC filing metadata
- accession: 0001640334-26-000554
- form_type: 8-K
- ticker: ARTL
- cik: 0001621221
- company_name: ARTELO BIOSCIENCES, INC.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1621221/000164033426000554/0001640334-26-000554-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1621221/000164033426000554/artl_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-26-000554
- JSON: https://secwatch.observer/filing/0001640334-26-000554.json
- Plain text: https://secwatch.observer/filing/0001640334-26-000554.txt

## Key facts
- Material Agreements
  ARTELO BIOSCIENCES, INC. entered into Securities Purchase Agreement with Labrys Fund II, L.P. valued at aggregate principal amount of $315,000.00 (effective 2026-03-20).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Labrys Fund II, L.P.
  - Value: aggregate principal amount of $315,000.00
  - Effective: 2026-03-20
  source text: On March 20, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a Securities Purchase Agreement, dated as of March 20, 2026 (the “Purchase Agreement”), with Labrys Fund II, L.P., a Delaware limited partnership (“Labrys”), pursuant to which the Company issued a 10% promissory note in the aggregate principal amount of $315,000.00, which includes an original issue discount of $15,000.00, for an aggregate purchase price of $300,000.00 (the “Note”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621221/000164033426000554/0001640334-26-000554-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.